Neurogene NGNE 深 沪
等待开盘 11-13 09:30:00 美东时间
23.90
-1.200
-4.78%
华盛通- 最 高24.99
- 今 开24.77
- 成交量 23.79万股
- 最 低 22.70
- 昨 收 25.10
- 总市值 4.95亿
- 52周最高 43.66
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 15.93
- 委 比 34.29%
- 总股本 2070.09万
- 历史最高 362.60
- 量 比 0.70
- 振 幅 9.12%
- 历史最低 6.875
- 每 手 1
- 风险率 6.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT reported Q3 2026 financial results and operational highlights, including completion of enrollment and randomization for the 4FRONT-2 Phase 3 trial for wet AMD, initiation of the 4SIGHT Phase 3 trial for DME, and strengthening of regulatory teams with Dr. Eric Floyd's appointment. The company expects topline data from both 4FRONT trials in 2027 and has $375 million in cash to fund operations into 2028.
11-12 21:05
美股大行评级 | 富国银行维持英伟达"超配"评级！但目标价从315美元降至300美元
今日重点评级关注：花旗：维持Faeth Therapeutics"买入"评级，目标价从55美元升至60美元；HC Wainwright & Co.：维持Ocular Therapeutix"买入"评级，目标价从25美元升至28美元
11-11 10:50
HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $60
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target from $65 to $60.
11-10 20:13
Neurogene Q3 EPS $(1.05) Beats $(1.36) Estimate
Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.36) by 22.79 percent. This is a 6.06 percent decrease over losses of $(0.99) per share from the same period last year.
11-09 20:54
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated Design
New data showing rapid and durable full-length MECP2 expression in vivo with single-stranded AAV support improvements observed in NGN-401 Phase 1/2 trial New in vivo data demonstrate that miRNA-based auto-regulatory technology is not responsive to endogenous MeCP2 levels on a cell-by-cell basis Prec...
10-27 19:32
美股大行评级 | 潜在涨幅179.23%！奥本海默上调Aurora Innovation目标价至16美元，维持"跑赢大市"评级
今日重点评级关注：奥本海默：维持Aurora Innovation"跑赢大市"评级，目标价从15美元升至16美元；富国银行：维持Applied Digital"超配"评级，目标价从50美元升至55美元
10-09 16:25
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
J.P. Morgan has initiated coverage of gene therapy developer Neurogene (NGNE) with an Overweight recommendation, highlighting its lead program NGN-401 targeting a rare neurodevelopmental disorder know...
10-09 01:31
JP Morgan Initiates Coverage On Neurogene with Overweight Rating, Announces Price Target of $60
JP Morgan analyst Priyanka Grover initiates coverage on Neurogene (NASDAQ:NGNE) with a Overweight rating and announces Price Target of $60.
10-08 21:56
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
